New pill aims to fix Chemo-Related low platelets in breast cancer

NCT ID NCT07257809

Recruiting now Disease control Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a drug called Hetrombopag to raise platelet counts in 56 breast cancer patients who developed low platelets (thrombocytopenia) after T-DM1 therapy. The goal is to see if the drug can safely keep platelets at a safe level so patients can continue their cancer treatment without needing platelet transfusions. Participants take Hetrombopag pills daily for two weeks per cycle, and researchers will monitor platelet counts and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hetrombopag Olamine Tablets
What this could lead to: If successful, this could offer a way to manage low platelets in breast cancer patients, allowing them to continue T-DM1 therapy without delays or transfusions.
What could go wrong: This is a small, early-phase study with only 56 participants and no comparison group, so results may not apply broadly. The drug may not work for everyone or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer thrombocytopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THROMBOCYTOPENIA

Contacts and locations

Locations

Sun Yat-sen Memorial Hospital
RECRUITING

Guangzhou, Guangdong, 510120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.